Una evaluación económica de la estimulación del nervio vago como tratamiento adyuvante a medicamentos anticonvulsivos para el tratamiento de la epilepsia resistente a medicamentos en los Estados Unidos.
PMID: 36691763 · 2023
C, h, r, i, s, t, o, p, h, e, r, , R, a, s, p, i, n, ;, , E, d, w, a, r, d, , F, a, u, g, h, t, ;, , J, e, a, n, n, e, , A, r, m, a, n, d, ;, , F, r, a, n, c, e, s, c, a, , B, a, r, i, o, n, ;, , V, i, c, k, i, , P, o, l, l, i, t, ;, , J, o, a, n, n, a, , M, u, r, p, h, y, ;, , V, a, n, e, s, s, a, , D, a, n, i, e, l, s, o, n
Publicidad
Resumen
People with recurrent epileptic seizures are typically treated with anti-seizure medications (ASMs). Around a third of epilepsy patients fail to achieve an adequate response to ASMs and may be eligible to receive vagus nerve stimulation (VNS) therapy for their drug-resistant epilepsy (DRE) if they are unsuited to surgery. VNS received approval from the United States (US) Food and Drug Administration agency. However, there has to date been no comprehensive cost effectiveness evaluation of VNS wit
Publicidad
Fuente oficial
Ver en PubMed →Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.